XORTX Therapeutics Inc. (XRTX) Stock Score, Valuation & Financial Research

XORTX Therapeutics Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for XRTX

XORTX Therapeutics Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.70. These figures are a research snapshot, not a buy or sell recommendation.

What XORTX Therapeutics Inc. does

XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD). Another key candidate is XRx-101, an agent aimed at reducing uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications. Furthermore, they are developing XRx-221, a series of xanthine oxidase inhibitors intended for the management of diabetic nephropathy. XORTX also collaborates with the Icahn School of Medicine on research investigating acute kidney injury and hyperuricemia among hospitalized COVID-19 patients. The company's operations are headquartered in Vancouver, Canada.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

XORTX Therapeutics is a clinical-stage pharmaceutical company that does not currently generate revenue. Its business model focuses on the research and development of innovative therapies for gout and progressive kidney disease, with the goal of eventually commercializing these products or entering into licensing agreements.

Products and services

  • The company is developing three clinical-stage programs: XRx-026 for the treatment of gout, XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney and organ injury associated with respiratory virus infections.

Brands and product families

  • XORLO — A proprietary product candidate in the gout program. Source

Business strengths to evaluate

  • Clinical-stage pipeline targeting orphan disease indications Source

Business risks and research considerations

  • History of significant operating losses and accumulated deficit Source
  • Dependence on additional financing to continue operations Source

Sources: Company research source · XORLO

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

XRTX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.70
Market capitalization:
473.43K (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -3.75M
Free cash flow:
USD -2.82M
Cash:
USD 992.85K
Total debt:
USD 37.22K
EPS:
USD -2.74

What stands out

  • Free cash flow is USD -2.82M, negative for the stored period.
  • The balance sheet shows USD 992.85K of cash versus USD 37.22K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 955.63K using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for XRTX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can XRTX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is XRTX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for XRTX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of XRTX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research XRTX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.